QualityStocks

[QualityStocks]

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) Focuses on Development, Commercialization of Handheld POC Diagnostic Device to Rapidly Detect Heart Attack

Healthcare technology company Zenosense (OTC: ZENO) is primarily focused on the development and commercialization of MIDS Cardiac™ through the company’s joint venture ownership in MIDS Medical Limited (“MML”). An article discussing the company reads: “True, high-sensitivity devices are not available in smaller handheld devices at the POC, where they are most needed. This is because the optical detection systems generally used in central laboratory analyzers cannot be effectively miniaturized. … MIDS Cardiac uses the patented MIDS technology platform, exclusively available to MML. Instead of using conventional optical detection, MIDS can detect and quantify assay beads nano-magnetically. This means it can be incorporated in a small device expected to achieve highly sensitive detection levels, which can support true high sensitivity cardiac biomarker tests in emergency settings, at the POC.”

To view the full article, visit http://ibn.fm/38sIy

About Zenosense, Inc.

Zenosense Inc.’s primary focus, through its joint venture ownership in MIDS Medical Ltd., is the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiac™, and is also the holder of an exclusive global license agreement to develop and market effective medical devices for use in hospitals and primary healthcare settings targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients. For more information, visit the company’s website at www.ZenoSense.com.